Status and phase
Conditions
Treatments
About
The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.
Full description
Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Has discontinued treatment with mitapivat before completing the antecedent study;
Known allergy or other contraindication to mitapivat or its inactive ingredients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, Opadry II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD&C Blue #2]);
Any medical, hematologic, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study also excluded are:
Primary purpose
Allocation
Interventional model
Masking
6 participants in 1 patient group
Loading...
Central trial contact
Agios Medical Affairs
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal